Ondansetron, 2 mg/ml 2 ml 5 pcs

Ondansetron is an antiemetic.

Effectively prevents and eliminates nausea and vomiting occurring against the background of anti-tumor chemotherapy or radiation therapy, as well as in the postoperative period.

The mechanism of action is due to the ability of ondansetron to selectively block serotonin 5-HT3 receptors.

The stimulation of afferent fibers of the vagus nerve by serotonin released from enterochromaffin cells of the gastrointestinal mucosa is believed to play an important role in the occurrence of nausea and vomiting during antitumor therapy.

Blocking 5-HT3 receptors, ondansetron prevents the onset of the gag reflex. In addition, ondansetron inhibits central links of the gag reflex by blocking 5-HT3-receptors of the floor of the IV ventricle (area postrema).

Indications

Prevention of nausea and vomiting during antitumor chemotherapy or radiation therapy; prevention and treatment of nausea and vomiting in the postoperative period.

Pharmacological effect

Ondansetron is an antiemetic drug.

Effectively prevents and eliminates nausea and vomiting that occurs during antitumor chemotherapy or radiation therapy, as well as in the postoperative period.

The mechanism of action is due to the ability of ondansetron to selectively block serotonin 5-HT3 receptors.

It is believed that stimulation of the afferent fibers of the vagus nerve by serotonin released from the enterochromaffin cells of the gastrointestinal mucosa plays an important role in the occurrence of nausea and vomiting during antitumor therapy.

By blocking 5-HT3 receptors, ondansetron prevents the gag reflex. In addition, ondansetron inhibits the central parts of the gag reflex, blocking 5-HT3 receptors in the bottom of the fourth ventricle (area postrema).

Special instructions

When used in patients with moderate and severe liver dysfunction, it is not recommended to exceed a dose of 8 mg/day. Ondansetron is used with caution during abdominal surgery, because its use may mask progressive intestinal obstruction.

Active ingredient

Ondansetron

Composition

1 ampoule contains:

Active substance:

ondansetron (as hydrochloride dihydrate) 2 mg.

Contraindications

Hypersensitivity, children’s age – for rectal administration (up to 2 years – for oral and parenteral administration).

Side Effects

From the gastrointestinal tract: constipation/diarrhea, dry mouth, hiccups, transient increase in AST and ALT levels.

From the nervous system and sensory organs: headache, dizziness, spontaneous movement disorders and convulsions, impaired visual acuity, extrapyramidal disorders (with parenteral use).

From the cardiovascular system and blood (hematopoiesis, hemostasis): fainting, chest pain, in some cases with ST segment depression, bradycardia, arrhythmia, arterial hypotension.

Allergic reactions: urticaria, bronchospasm, laryngospasm, angioedema, anaphylaxis.

Other: fever, sensation of heat, flushing, hypokalemia, hypercreatinemia, local reactions (pain, redness and burning at the injection site); burning in the anus and rectum (suppositories).

Interaction

Since ondansetron is metabolized by the liver enzyme system (cytochrome P450), caution is required when combined with inducers of the CYP2D6 and CYP3A isoenzymes of cytochrome P450 (barbiturates, carbamazepine, griseofulvin, nitrous oxide, papaverine, phenylbutazone, phenytoin and probably other hydantoins, rifampicin, tolbutamide), as well as inhibitors of P450 isoenzymes CYP2D6 and CYP3A (allopurinol, macrolide antibiotics, antidepressants-MAO inhibitors, chloramphenicol, cimetidine, estrogen-containing oral contraceptives, diltiazem, disulfiram, erythromycin, valproic acid, sodium valproate, fluconazole, fluoroquinolones, isoniazid, ketoconazole, lovastatin, metronidazole, omeprazole, propranolol, quinidine, quinine, verapamil).

Overdose

Symptoms: increased severity of adverse reactions.

Treatment: symptomatic therapy. A specific antidote is unknown.

Manufacturer

Novosibkhimpharm, Russia